AbbVie

AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

immunology · 6 min

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

U.S. Federal Trade Commission · immunology · 5 min

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.

AbbVie Secures FDA Approval for ImmunoGen's Elahere

FDA · rare blood cancers · 6 min

Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere

AbbVie Plans Layoffs: Implications for the Pharma Industry

FDA · 6 min

Structured plan for AbbVie Plans Layoffs: Implications for the Pharma Industry

AbbVie's Decnupaz Secures FDA Approval for Rare Blood Cancer

FDA · blastic plasmacytoid dendritic cell neoplasm · 5 min

The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.

UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape

FDA · psoriatic arthritis · 8 min

UCB's Bimzelx (bimekizumab) has secured significant approvals for psoriatic arthritis, demonstrating strong efficacy in head-to-head trials. This success reshapes the competitive landscape and presents key opportunities and challenges for pharmaceutical business development and investment.

UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape

FDA · psoriatic arthritis · 8 min

UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.

UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis

FDA · psoriatic arthritis · 7 min

UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.

AbbVie Secures FDA Approval for ImmunoGen's Elahere in Rare Blood Cancer

FDA · rare blood cancer · 2 min

AbbVie has received FDA approval for Elahere, a significant advancement in the treatment of rare blood cancers. This article explores the implications for pharmaceutical teams and investors.

AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma

2 min

AbbVie and GSK have made significant strides in patient reputation in the UK. This article explores the implications for the pharmaceutical industry.

AbbVie and GSK Surge in UK Patient Reputation Rankings

3 min

AbbVie and GSK have made significant strides in patient reputation rankings in the UK. This article explores the implications for the pharmaceutical sector.

Novartis and AbbVie Layoffs: Implications for the Pharma Industry

2 min

Novartis and AbbVie are planning significant layoffs this summer. This article examines the implications for the pharmaceutical industry and business teams.